Gain Therapeutics (NASDAQ:GANX) Earns Buy Rating from Analysts at Roth Mkm

Roth Mkm started coverage on shares of Gain Therapeutics (NASDAQ:GANX) in a report issued on Friday, Marketbeat Ratings reports. The firm issued a buy rating and a $7.00 target price on the stock.

GANX has been the topic of a number of other research reports. Chardan Capital reiterated a “buy” rating and set a $6.00 price objective on shares of Gain Therapeutics in a research note on Friday, August 9th. Oppenheimer reiterated an “outperform” rating and set a $8.00 price objective on shares of Gain Therapeutics in a research note on Wednesday, August 14th. Finally, HC Wainwright reiterated a “buy” rating and set a $8.00 price objective on shares of Gain Therapeutics in a research note on Monday, November 25th. Four analysts have rated the stock with a buy rating and one has given a strong buy rating to the stock. According to MarketBeat, Gain Therapeutics currently has a consensus rating of “Buy” and a consensus target price of $7.25.

Gain Therapeutics Trading Up 4.7 %

NASDAQ GANX opened at $1.79 on Friday. The firm has a market capitalization of $47.47 million, a price-to-earnings ratio of -1.63 and a beta of 0.21. The company’s 50 day moving average price is $2.09 and its 200 day moving average price is $1.68. Gain Therapeutics has a one year low of $0.89 and a one year high of $5.33. The company has a debt-to-equity ratio of 0.04, a quick ratio of 2.99 and a current ratio of 2.99.

Hedge Funds Weigh In On Gain Therapeutics

A number of hedge funds have recently added to or reduced their stakes in the business. Warberg Asset Management LLC acquired a new stake in Gain Therapeutics in the second quarter worth about $66,000. Renaissance Technologies LLC lifted its holdings in Gain Therapeutics by 154.2% in the second quarter. Renaissance Technologies LLC now owns 118,700 shares of the company’s stock worth $152,000 after purchasing an additional 72,000 shares during the period. Geode Capital Management LLC lifted its holdings in Gain Therapeutics by 48.0% in the third quarter. Geode Capital Management LLC now owns 271,972 shares of the company’s stock worth $484,000 after purchasing an additional 88,236 shares during the period. Finally, Hohimer Wealth Management LLC acquired a new stake in Gain Therapeutics in the second quarter worth about $422,000. Institutional investors and hedge funds own 11.97% of the company’s stock.

About Gain Therapeutics

Gain Therapeutics, Inc, a biotechnology company, develops novel small molecule therapeutics to treat diseases across various therapeutic areas. Its drug discovery platform Magellan discovers novel allosteric binding sites in a disease; identifies proprietary small molecules that bind these sites to modulate protein function; and treats the underlying cause of the disease.